Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448068 · ClinicalTrials.gov registry record · Phase 2
Perioperative Ketamine for Pain With Gastric Bypass
A Phase 2 study of Ketamine and Laparoscopic Gastric Bypass Surgery, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT03448068: Completed Phase 2 study of Ketamine and Laparoscopic Gastric Bypass Surgery, sponsored by Mayo Clinic.
NCT03448068 is a Phase 2 study of Ketamine and Laparoscopic Gastric Bypass Surgery that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants, above the 31-participant average among 3 other Ketamine trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03448068, a Phase 2 study of Ketamine and Laparoscopic Gastric Bypass Surgery, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Opioid medications such as morphine, hydrocodone and oxycodone are standard for treating pain after surgery, however there are disadvantages. Because of the way opioids work, gastric bypass patients may have an increased risk of having sedation or problems with breathing. In patients with sleep apnea, opioids may increase the risk of severe apnea. Ketamine is an alternative pain medicine that can be used to treat pain after surgery and may have fewer effects on breathing. Using ketamine as part of the regimen may be a better choice for laparoscopic gastric bypass patients. This study is being done to find out if intraoperative ketamine infusion combined with continuation for twenty-four hours post-surgery provides superior pain control and decreases post-operative opioid use versus standard non-ketamine therapy.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Standard therapy
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03448068
The ClinicalTrials.gov registry entry for NCT03448068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 3 other Ketamine trials with a reported enrollment target (10% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ketamine appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT03448068 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT03448068 about?
NCT03448068 is a clinical study titled "Perioperative Ketamine for Pain With Gastric Bypass". Opioid medications such as morphine, hydrocodone and oxycodone are standard for treating pain after surgery, however there are disadvantages. Because of the way opioids work, gastric bypass patients may have an increased risk of having sedation or problems with breathing. In patients with sleep apne...
What is the current status of trial NCT03448068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-04-16. Estimated completion is 2020-01-09.
What conditions does trial NCT03448068 study?
This clinical trial studies the following conditions: Ketamine, Laparoscopic Gastric Bypass Surgery.
What interventions are being tested in trial NCT03448068?
The interventions under investigation include: Ketamine (DRUG), Standard therapy (DRUG).
Who is sponsoring clinical trial NCT03448068?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03448068 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ketamine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
RECRUITING · Phase 3
-
Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients
RECRUITING
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.